Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
about
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma CommitteeCongenital infantile fibrosarcoma: Association with bleeding diathesis.What is new in the biology and treatment of pediatric rhabdomyosarcoma?Age-related toxicity in patients with rhabdomyosarcoma: a report from the children's oncology group.Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from thRhabdomyosarcoma in infants younger than 1 year: a report from the Children's Oncology Group.Ancestry and pharmacogenetics of antileukemic drug toxicityLocal control with reduced-dose radiotherapy for low-risk rhabdomyosarcoma: a report from the Children's Oncology Group D9602 studyLocal control and outcome in children with localized vaginal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma committee of the Children's Oncology Group.Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology GroupCharacterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature.Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology GroupSevere Hepatic Sinusoidal Obstruction Syndrome in a Child Receiving Vincristine, Actinomycin-D, and Cyclophosphamide for Rhabdomyosarcoma: Successful Treatment with DefibrotideVincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature.The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy.Selecting multimodal therapy for rhabdomyosarcoma.Targeted therapy in pediatric and adolescent oncology.What is new in rhabdomyosarcoma management in children?Liposomal forms of anticancer agents beyond anthracyclines: present and future perspectives.Population pharmacokinetic investigation of actinomycin-D in children and young adults.Vincristine and Vinblastine: Is checking bilirubin mandatory in children with Brain Tumors?Pharmacology and pharmacokinetics of imatinib in pediatric patients.Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group
P2860
Q30584978-F09249E8-D14F-4E02-A52C-CCF3CABD4972Q33396263-989DD844-ACCB-4171-901B-2F69C6C584AAQ33411676-A60EB6AC-82AA-495E-9420-4F78971CF560Q33895506-3DA16FD6-936D-4BA5-B269-A79348CDEC68Q34381149-066071FD-D88D-4D28-8930-2FF25022826FQ34879307-94ECEDBE-8303-401D-9047-6F7D8BFE6F15Q35119012-2141C7F8-71AB-4545-AE8E-47D0D70DD059Q35828717-C90DF3E3-7C47-45D4-ABA2-A6AA6B7BFC08Q35834688-D37BB4A9-CCB1-44C2-99D8-71E33B8A4C16Q36284400-9F751087-7794-4581-90AE-746F2E41335EQ36306185-CECFBDA9-CA45-4A88-AAE0-8083593CBBEDQ36533306-71C2D6E4-EA9E-4327-B4DB-E90C8F52F580Q36806598-ECEF168C-0535-4BF7-881D-CD91D6D873D7Q37037513-A5E01D23-0E76-4C1E-BCB9-1C230307117CQ37120672-1C01D5BB-050A-4D9E-85A5-E3EE13ED616CQ37367452-24B70840-DD48-48E3-976E-DE7500ED8B70Q37412294-FBC59249-0284-4569-AD27-41329C4A810DQ37414178-B7E65CB9-769C-4D6A-B54E-F2A112EC7A27Q37521422-6FBF3FA6-1BA5-420E-8133-3684648DF203Q37782096-9D92858B-1FC6-4974-9729-4662C099072EQ37869437-DB2F7EBF-D49C-419A-9F60-AE79EDAECA16Q38050831-293250CF-A01D-4461-83A8-CA7508A81700Q38242272-11AA9E48-B956-4CCF-B907-C9B81D48E37EQ40142021-BD4C49CE-E863-471F-975E-80D3DE3D417EQ46620055-C2963378-48D0-49CC-AA3B-1AFBEC3C09DAQ50094239-C126D091-FBA0-470A-9577-841AFE0C20C4Q58792074-A63CADA3-FCAD-4F13-826F-A552857FACB3
P2860
Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@en
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@nl
type
label
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@en
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@nl
prefLabel
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@en
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@nl
P2093
P356
P1476
Age is a risk factor for chemo ...... nomycin, and cyclophosphamide.
@en
P2093
P304
P356
10.1200/JCO.2004.08.075
P407
P577
2004-05-01T00:00:00Z